NICE
@NICEComms
Followers
240K
Following
3K
Media
9K
Statuses
17K
Official feed of NICE - National Institute for Health and Care Excellence. We produce evidence-based health and social care guidance. Tweets by the comms team.
London and Manchester, UK
Joined October 2009
Digital cardiac rehab could be transformative for groups currently underserved by traditional programmes, NICE's HealthTech programme director, Dr Anastasia Chalkidou says, welcoming NICE's recommendation⬇️
0
0
0
NICE now recommends 7 digital cardiac rehab platforms, making it easier to do recovery sessions from home. Currently only 41% of eligible patients access traditional programmes – digital options could help more people get the support they need: https://t.co/EVfSQlazk6
1
0
0
In February, we approved a new once-weekly drug for severe haemophilia A (for people aged 2 and over) just a week after @MHRAgovuk licence. This time-saving treatment is a welcome alternative to more frequent therapies, helping to improve patients' lives: https://t.co/y9VNLbdJGw
0
0
0
We're seeking professional and patient experts to join our committee for technologies for the rapid diagnosis of endometriosis. Help develop guidance by completing our questionnaire: https://t.co/KluVdF1V0k 📆Apply by 12 Dec
2
3
2
This important @WellcomeTrust funding will support safe development of digital mental health technologies. As part of the 10 year plan, NICE is committed to giving patients fairer access to the best digital tools, diagnostics and medical devices⤵️ https://t.co/8LPmO6ZPuJ
indepth.nice.org.uk
At NICE, we’re poised to deliver key commitments in the government’s 10 year plan for health and care.
📲 MHRA & @NICEComms have secured £2M from @wellcome to make digital mental health tech – from apps to AI therapies – safer, more effective & trustworthy Clear guidance + better evidence = patients & clinicians can use tools with confidence ✅ 🔗: https://t.co/fbKRNExd2c
1
2
2
Cabotegravir is administered as an injection every two months in specialist sexual health clinics. This approach addresses a critical gap for people who cannot have daily medication, with up to 1,000 people expected to benefit in England per year. #WorldAidsDay
0
1
1
Marking #WorldAIDSDay: we recently approved cabotegravir, the first injectable HIV prevention treatment for people who can't take daily PrEP tablets. Cabotegravir offers a new PrEP option for high-risk individuals, used alongside safer sex practices: https://t.co/ADvEKtTxSW
1
5
6
Join our webinar to learn what changes to NICE's cost-effectiveness thresholds mean in practice. Hear from NICE's senior leaders about plans to introduce these changes: https://t.co/X8PBT8QCee
0
1
1
The government has announced an increase to the threshold we use to evaluate the cost-effectiveness of new NHS medicines. We are now working to introduce these changes fairly and swiftly to provide clarity and certainty for companies and patient groups: https://t.co/sxnJfgsLCk
nice.org.uk
Changes to NICE’s cost-effectiveness thresholds confirmed
1
6
8
We’re highlighting some of our biggest stories from 2025 - from recommending a gene editing therapy for people with sickle cell disease, to the NHS 10 year plan, and record numbers of positive recommendations for blood cancer treatments. 🔗 https://t.co/wV20OMxc9Y
#NICEin2025
2
1
3
📊@CVDPREVENTaudit's new data pack supports ICBs with hypertension and lipid management. Get clear insights on NICE guidance implementation and spot opportunities to improve patient outcomes⬇️
Quality Improvement Data Packs tailored for each ICB are now available on the website. By downloading your ICB’s pack, you can view bespoke data and get tips and resources for quality improvement in the four key CVDPREVENT indicators.📈Find them here : https://t.co/cXXjqlm2Sq
0
1
2
The results? Early best practice principles for using generative AI in economic modelling, helping drive international standards in health economics. Read our position statement:
nice.org.uk
The use of artificial intelligence (AI) methods, from relatively well-established machine learning approaches to newer and more complex generative AI, offers several potential benefits for the core...
0
0
2
How can AI transform health technology evaluation? Our HTA Innovation Lab has been exploring how generative AI could revolutionise health economic evaluation, a crucial but resource-heavy part of assessing new health technologies:
nice.org.uk
1
0
2
It’s one year since the @BTSrespiratory, @NICEComms and SIGN published a UK-wide Joint Guideline on Asthma: diagnosis, monitoring and chronic asthma management. Read more: https://t.co/QT1yFuJNag
0
2
4
Health minister Ashley Dalton said that supporting new treatments with fewer side effects and shorter hospital stays was part of work to build an NHS fit for the future.
1
0
0
Helen Knight, our director of medicines evaluation, has welcomed the recommendation of obecabtagene autoleucel, saying it has the potential to be a life-saving drug which could significantly reduce the time people need to spend in hospital.
1
0
0
Hundreds of people with a rare and aggressive blood cancer could be set to benefit from a potentially life-saving treatment developed by a British spinout company and recommended by NICE today. Find out more about obecabtagene autoleucel: https://t.co/yWX7RgxxtZ
1
2
6
NICE and @NHSEngland's innovative antimicrobial payment model aims to tackle #AntimicrobialResistance - one of the biggest global health threats. Learn more about this subscription-based model: https://t.co/DjJ6AcF1CF #AMR #WAAW2025
0
1
1
How does NICE ensure the NHS gets guidance on what matters most? Each year we publish our forward view, giving a clear line of sight on guidance that may affect service planning and commissioning decisions. Learn more⬇️ https://t.co/mtAFUyxeJe
0
0
1
New treatment recommended for condition affecting protein build-up in the heart. Read NICE's final draft guidance on vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy: https://t.co/5fvf536jdY
0
0
3